Menin: from molecular insights to clinical impact
Name
IEPI_A_2485019_O.pdf
Description
Published version
Size
2.35 MB
Format
Adobe PDF
Checksum (MD5)
570e90f002316f46fd24683bf5b87e72
Author(s)
Brown, Margaret R
Soto-Feliciano, Yadira M
Date Issued
March 28, 2025
Journal
Epigenomics
Publisher
Informa UK Limited
Citation
Brown, M. R., & Soto-Feliciano, Y. M. (2025). Menin: from molecular insights to clinical impact. Epigenomics, 1–17.
Version
Final published version
Abstract
Menin, the protein product of the MEN1 gene, is essential for development and has been implicated in multiple different cancer types. These include leukemias and several different solid tumors, including neuroendocrine tumors. Menin interacts with many different protein partners and genomic loci in a context-dependent manner, implicating it in numerous cellular processes. The role of Menin varies across tumor types as well, acting as a tumor suppressor in some tissues and an oncogenic co-factor in others. Given the role of Menin in cancer, and particularly its oncogenic role in acute myeloid leukemia, the development of Menin inhibitors has been an expanding field over the past 10-15 years. Many inhibitors have been in clinical trials and one has recently received approval from the Food and Drug Administration (FDA). In this review, we explore the role of Menin in multiple cancer types, the development of Menin inhibitors and their clinical applications and what the focus of the field should be in the next 5-10 years to expand the use and efficacy of these drugs.
MIT Department
Massachusetts Institute of Technology. Department of Biology
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1080/17501911.2025.2485019
